|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
10
|
|
pubmed:dateCreated |
1999-11-16
|
|
pubmed:abstractText |
H-2 class I-negative, HLA-A2.1-transgenic HHD mice were used for a comparative evaluation of the immunogenicity of HLA-A2.1-restricted human tumor-associated cytotoxic T lymphocyte (CTL) epitopes. A hierarchy was established among these peptides injected into mice in incomplete Freund's adjuvant which correlates globally with their capacity to bind and stabilize HLA-A2.1 molecules. Co-injection of a helper peptide enhanced most CTL responses. In contrast, classical HLA class I-transgenic mice which still express their own class I molecules did not, in most cases, develop HLA-A2.1-restricted CTL responses under the same experimental conditions. Different monoepitope immunization strategies of acceptable clinical usage were compared in HHD mice. Recombinant Ty-virus-like particles, or DNA encoding epitopes fused to the hepatitis B virus middle envelope protein gave the best results. Using this latter approach and a melanoma-based polyepitope construct, CTL responses against five distinct epitopes could be elicited simultaneously in a single animal. Thus, HHD mice provide a versatile animal model for preclinical evaluation of peptide-based cancer immunotherapy.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0014-2980
|
|
pubmed:author |
pubmed-author:FiratHH,
pubmed-author:Garcia-PonsFF,
pubmed-author:GarciaZZ,
pubmed-author:JackR WRW,
pubmed-author:JungGG,
pubmed-author:KosmatopoulosKK,
pubmed-author:Langlade-DemoyenPP,
pubmed-author:LemonnierF AFA,
pubmed-author:MateoLL,
pubmed-author:MichelM LML,
pubmed-author:PascoloSS,
pubmed-author:ScardinoAA,
pubmed-author:SuhrbierAA,
pubmed-author:TourdotSS
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
29
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
3112-21
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:10540322-Amino Acid Sequence,
pubmed-meshheading:10540322-Animals,
pubmed-meshheading:10540322-Antigens, CD8,
pubmed-meshheading:10540322-Cancer Vaccines,
pubmed-meshheading:10540322-Disease Models, Animal,
pubmed-meshheading:10540322-Epitopes, T-Lymphocyte,
pubmed-meshheading:10540322-H-2 Antigens,
pubmed-meshheading:10540322-HLA-A2 Antigen,
pubmed-meshheading:10540322-Hepatitis B Core Antigens,
pubmed-meshheading:10540322-Humans,
pubmed-meshheading:10540322-Immunodominant Epitopes,
pubmed-meshheading:10540322-Immunotherapy, Active,
pubmed-meshheading:10540322-Melanoma,
pubmed-meshheading:10540322-Melanoma, Experimental,
pubmed-meshheading:10540322-Mice,
pubmed-meshheading:10540322-Mice, Inbred C57BL,
pubmed-meshheading:10540322-Mice, Knockout,
pubmed-meshheading:10540322-Mice, Transgenic,
pubmed-meshheading:10540322-Molecular Sequence Data,
pubmed-meshheading:10540322-Peptides
|
|
pubmed:year |
1999
|
|
pubmed:articleTitle |
H-2 class I knockout, HLA-A2.1-transgenic mice: a versatile animal model for preclinical evaluation of antitumor immunotherapeutic strategies.
|
|
pubmed:affiliation |
Unité d'Immunité Cellulaire Antivirale, Département SIDA-Rétrovirus, Institut Pasteur, Paris, France. hfirat@pasteur.fr
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|
